Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

Selux Diagnostics, Inc., Charlestown MA

Investigators

Abstract

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim 2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will compare Selux NGP performance against legacy AST systems and reference methods. By improving system workflows and benchmarking AST performance across legacy systems CRP funding will help position Selux NGP as the dominant AST platform of the future.